Inhibrx Biosciences, Inc.

What they do

Inhibrx Biosciences develops novel biologic therapeutic candidates using proprietary modular protein engineering platforms. Its two clinical programs are ozekibart, a tetravalent DR5 agonist being tested in chondrosarcoma, Ewing sarcoma, colorectal cancer and other solid tumors, and INBRX-106, a hexavalent OX40 agonist in non-small cell lung cancer and head and neck squamous cell carcinoma. The company has no approved products and has never generated product revenue; it operates as a stand-alone public company following the May 2024 separation from its former parent.

Revenue drivers

• Product sales — None. The company has never generated revenue from product sales and has no approved products.
• License and assignment agreements — The only reported revenue source: $1.3 million in 2025 and $1.3 million in Q2 2025 from completing transfer of licenses, materials and know-how under an agreement with Scithera, Inc.
• Annual revenue history — Revenue was $1.8 million in 2023, $200,000 in 2024, and $1.3 million in 2025; no revenue was recognized in Q3 2025, Q4 2025, Q1 2026, or Q2 2026.
• Future revenue — Dependent on regulatory approval and commercialization of ozekibart or INBRX-106, neither of which is approved.

Recent performance

Q2 2026 net loss was $36.7 million, or $2.34 per share, versus a $28.7 million net loss ($1.85 per share) in Q2 2025. R&D expense rose to $23.9 million from $22.3 million, driven by clinical trial costs and contract manufacturing for the ozekibart BLA. G&A expense rose to $8.3 million from $6.4 million on pre-commercialization market access and launch preparation. No revenue was recognized in Q2 2026; cash and equivalents were $133.3 million as of June 30, 2026, rising to $219.5 million as of August 6, 2026 after the Oxford loan amendment.

Strategy

The company is prioritizing the ozekibart chondrosarcoma BLA, accepted for filing by the FDA in June 2026 with a PDUFA goal date of April 14, 2027, and is preparing for potential commercialization. It initiated two additional Phase 1 CRC cohorts in Q2 2026: ozekibart with Folfiri and Avastin in second line, and with Lonsurf and Avastin in third/fourth line. It plans a Q4 2026 FDA meeting on a first-line registrational CRC trial and a possible accelerated pathway in fourth-line CRC. It also plans to report PFS data from the randomized Phase 2 HNSCC trial of INBRX-106 plus pembrolizumab in Q3 2026. In July 2026 it amended its Oxford loan for up to $325.0 million in gross proceeds.

Risks

• No product revenue or profitability — The company has incurred significant operating losses since inception, has never generated product revenue, and may never become profitable.
• Need for additional capital — Management states it will need to raise substantial additional funds to advance development, and funding may not be available on acceptable terms or at all.
• Dependence on clinical success — The company depends heavily on ozekibart and INBRX-106, both clinical-stage candidates that may fail or face delays.
• Negative shareholder equity and debt load — As of June 30, 2026, total liabilities of $207.2 million exceeded total assets of $154.2 million, producing shareholder equity of negative $53.0 million, with long-term debt of $176.3 million.

Outlook

Management plans to report PFS data from the randomized Phase 2 HNSCC trial of INBRX-106 plus pembrolizumab in Q3 2026, and interim results from the two new ozekibart CRC cohorts in Q1 2027. A Q4 2026 FDA meeting is planned to discuss a first-line registrational CRC trial and a potential accelerated pathway for fourth-line CRC. The ozekibart BLA in conventional chondrosarcoma has an FDA PDUFA goal date of April 14, 2027.